It has been observed that the patients with shorter relapse‐free time had high BCL2/BAX ratio expression in a sample of Iranian BC cases which introduced BCL2/BAX expression ratio as a significant prognostic marker of low‐grade BC (Golestani Eimani et al., 2014). This evidence concerns the gene BCL2 and breast cancer.